Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Expression of WASF3 in patients with non-small cell lung cancer: Correlation with clinicopathological features and prognosis.
[wiskott-aldrich syndrome]
Wiskott-
Aldrich
syndrome
protein
family
member
3
(
WASF
3
)
is
required
for
invasion
and
metastasis
in
different
cancer
cell
types
,
and
has
been
demonstrated
to
possess
prognostic
value
in
various
types
of
human
cancer
.
However
,
to
the
best
of
our
knowledge
,
the
expression
profile
of
WASF
3
and
its
correlations
with
the
clinicopathological
features
of
non-
small
cell
lung
cancer
(
NSCLC
)
have
not
yet
been
described
.
In
the
present
study
,
the
mRNA
expression
levels
of
WASF
3
,
in
38
NSCLC
patients
and
in
matched
normal
tissues
,
were
assessed
using
quantitative
polymerase
chain
reaction
and
the
protein
expression
in
96
specimens
was
analyzed
using
immunohistochemistry
.
In
addition
,
patient
survival
data
were
collected
retrospectively
and
the
association
between
WASF
3
expression
and
five
-
year
overall
survival
was
evaluated
.
The
results
demonstrated
that
the
mRNA
expression
level
of
WASF
3
in
cancer
tissues
was
markedly
(
approximately
five
times
)
higher
compared
with
that
of
the
normal
tissues
.
The
WASF
3
protein
expression
profile
in
NSCLC
was
consistent
with
the
mRNA
expression
result
,
which
also
correlated
with
the
histological
subtype
and
tumor
stage
.
Furthermore
,
patients
with
WASF
3
-
positive
expression
were
associated
with
a
poorer
prognosis
compared
with
those
exhibiting
WASF
3
-
negative
expression
,
and
the
five
-
year
survival
rate
was
20
.
8
and
46
.
5
%
,
respectively
(
Kaplan-
Meier
;
log-rank
,
P
=
0
.
004
)
.
In
the
multivariate
analysis
,
which
included
other
clinicopathological
features
,
WASF
3
emerged
as
an
independent
prognostic
factor
(
relative
risk
,
0
.
463
;
95
%
CI
,
0
.
271
-
0
.
792
)
.
These
results
indicate
that
WASF
3
may
be
critical
in
the
pathogenesis
of
NSCLC
,
in
addition
to
being
a
valuable
prognostic
factor
for
NSCLC
patients
.
Further
investigations
are
required
to
identify
the
efficacy
of
WASF
3
as
a
potential
therapeutic
target
for
the
treatment
of
NSCLC
.
Diseases
Validation
Diseases presenting
"other clinicopathological features"
symptom
wiskott-aldrich syndrome
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom